Cognition Therapeutics, Inc. · NASDAQ:CGTX
Cognition Therapeutics — Investor Presentation (August 2024)
21 slides from Cognition Therapeutics's investor presentation, Aug 28, 2024
Slide 1: Targeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of Alzheimer's Disease
Targeting Amyloid Beta Oligomers: A Disruptive Approach to the Treatment of Alzheimer’s Disease August 2024
Slide 2: Forward-Looking Statements
2 FORWARD-LOOKING STATEMENTS This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. All statements contained in this presentation, other than statements of historical facts or statements that relate to present facts or curren
Slide 3: Overview
3 Overview OUR SOLUTION CT1812: An orally delivered small molecule that potently antagonizes amyloid oligomers via a unique mechanism of action ✓ PHASE 2 PoC data demonstrated ~40% mean improvement in cognitive measures vs placebo in mild-moderate AD ✓ PHASE 2 PoC in early-mild AD currently enrollin
Slide 4: Breaking News – SHINE Proof-of-Concept Phase 2 Study
4 • Pooled (100 and 300mg arms) CT1812 treatment slowed cognitive decline by 39% on ADAS-Cog 11 vs placebo • All key cognitive and functional outcome measures trending in favor of CT1812 • Efficacious dose with good safety profile • Well-designed and executed study • Supports advancing clinical deve
Slide 5: SHINE Phase 2 Safety and Efficacy Study in Mild-to-Moderate Alzheimer's Disease
5 SHINE Phase 2 Safety and Efficacy Study in Adults with Mild-to-Moderate Alzheimer’s Disease Inclusion and Exclusion • AD diagnosis • PET or CSF biomarker definition of AD • MMSE 18-26 • MRI w/o significant abnormality • No MDD, schizophrenia, bipolar disorder • Stable regimen of AChEI or memantine
Slide 6: SHINE Patient Population
6 • PET- or biomarker-confirmed Alzheimer’s disease • Majority of participants were female (60%), Caucasian (96%), approximately 72 years of age • Mean MMSE score upon entry: 21.37 • ~60% of patients were carriers of the ApoE4 gene • Characteristics well-balanced between all 3 arms SHINE Patient Pop
Slide 7: SHINE Cognitive Endpoints: ADAS-Cog 11 and MMSE
7 SHINE Cognitive Endpoints: ADAS-Cog 11 and MMSE Magnitude of ADAS-Cog 11 decline at 6 months similar to approved MAbs ADAS-Cog 11 MMSE Pooled vs. pbo: 70% slowing Pooled vs. pbo: 39% slowing Note: n's are at Day 182
Slide 8: SHINE Cognitive Endpoints: ADAS-Cog 13, Cognitive Composite
8 SHINE Cognitive Endpoints: ADAS-Cog 13, Cognitive Composite Consistent results across multiple cognitive endpoints ADAS-Cog 13 Cognitive Composite Pooled vs. pbo: 39% slowing Pooled vs. pbo: 50% slowing Note: n's are at Day 182
Slide 9: Summary of SHINE Safety and Tolerability Findings
9 • CT1812 demonstrated a favorable safety and tolerability profile • Most TEAEs were mild or moderate in severity • Similar percentages of adverse events in treated (76.5%) and placebo (78%) groups • No discontinuations due to AEs in the 100mg dose group • Most discontinuations were in 300mg dose g
Slide 10: SHINE Response at 6 Months Comparable to Approved MAbs
10 SHINE Response at 6 months Comparable to Approved MAbs Once-daily pill • no ARIA • 39% slowing at 6 months vs Leqembi’s 26% at 18 months 1. van Dyck C et al. Lecanemab in Early Alzheimer’s Disease (2023) NEJM 388:9-21 CLARITY1 : ADAS-Cog 14 response in early AD (MMSE 22-30) Adjusted Mean Change f
Slide 11: SHINE: Summary Exploratory Outcomes - Percent Slowing
11 SHINE: Summary Exploratory Outcomes - Percent Slowing Day 182 Effect as large or larger than approved MAbs ADAS-Cog 11 ADAS-Cog 13 MMSE Cognitive Composite CT1812 Pooled1 39% 39% 70% 50% Lecanemab2 (at 18mo) -- 26% (ADAS-Cog 14) -- 24% (ADCOMS) Donanemab3 (at 18 mo) -- 20% (ADAS-Cog 13) 16% (MMSE
Slide 12: START: Proof-of-Concept 540-Person Study in Early AD
12 START: Proof-of-Concept 540-Person Study in Early AD Funded through $81M NIA Grant Enrollment Criteria Treatment Period 18 months Assessments ‐ Ages 50-85 ‐ Diagnosis of MCI due to AD or mild AD dementia ‐ Brain amyloid via PET ‐ MRI ‐ MMSE: 20-30 ‐ Safety ‐ Cognitive and functional testing: ‐ CD
Slide 13: CT1812 is Also Being Investigated in Two Additional Indications
13 CT1812 is Also Being Investigated in two Additional Indications Alzheimer’s Disease Dementia with Lewy Bodies Dry AMD Geographic Atrophy
Slide 14: Dementias are Second Only to AD in Prevalence
14 • In the U.S. an estimated 1.4 million people1 have dementia with Lewy bodies (DLB) • It is estimated that 50-80% of patients with DLB have Aβ as well as α-synuclein2pathology • Core symptoms of DLB include: - Progressive cognitive decline - Fluctuating cognition with variations in attention - Im
Slide 15: SHIMMER: Proof-of-Concept Trial Investigating CT1812 in DLB
15 SHIMMER: Proof-of-Concept Trial Investigating CT1812 in DLB Sponsored by $30 M NIA grant • Randomization to oral CT1812 (100 or 300mg) or placebo • Enrolled 130 adults with mild-to-moderate DLB • Not powered for statistical significance • Topline results YE 2024 • Collaboration with LBDA and Univ
Slide 16: Rationale for CT1812 in Dry AMD/Geographic Atrophy
16 Rationale for CT1812 in Dry AMD/Geographic Atrophy Opportunity: crosses blood-retinal barrier to reach retina without an injection What is dAMD/GA Geographic atrophy (GA), the most advanced form of dry AMD, effects ~5M people WW and is associated with significant vision loss Unmet Need Current st
Slide 17: MAGNIFY: Phase 2 Proof-of-Concept Trial in dAMD/GA
17 MAGNIFY: Phase 2 Proof-of-Concept Trial in dAMD/GA Unique MoA targeting retinal pigment epithelium Enrollment Criteria Treatment Period 24 months Assessments ‐ Age: ≥ 50 ‐ Diagnosis of dry AMD ‐ BCVA ≥ 24 letters (ETDRS) ‐ GA lesion ≥ 2.5 and ≤17.5mm2 ‐ Change in GA lesion area (FAF) ‐ Ellipsoid
Slide 18: Completed Studies Support Potential in Mild-to-Moderate AD
18 Completed Studies Support Potential in Mild-to-Moderate AD SPARC2 • 23 participants • Preservation of brain atrophy via volumetric MRI • No change in SV2A treated or pbo SNAP3 • 3 participants • Rapid displacement of Aβ oligomers via CSF • Replication of preclinical findings via MEI SEQUEL1 • 16
Slide 19: The Promise of CT1812
19 The Promise of CT1812 • First-in-class Aβ oligomer antagonism via sigma-2 receptor • Consistent efficacy in Alzheimer’s disease studies - ARIA unlikely to occur based on MoA • Potential first-to-market for DLB • Potential first oral for dAMD/GA • Well tolerated safety profile anticipated • Oral a
Slide 20: Current Financial Position
20 Current Financial Position Cash and cash equivalents $28.5 M Expected cash runway into 2Q 2025 Grant funding for CT1812 studies Preclinical through Phase 2 ~$171 M Approximate funding used ($113.7 M) Remaining grant funding $57.3M As of June 30, 2024
Slide 21: Thank You
Tony Caggiano, MD, PhD CMO and Head of R&D acaggiano@cogrx.com Lisa Ricciardi President & CEO lricciardi@cogrx.com John Doyle Chief Financial Officer jdoyle@cogrx.com Thank You
Cognition Therapeutics — Investor Presentation (August 2024) on 6ix